Clinical Report: Evaluating Blinatumomab with DLI in Pediatric ALL

Overview

This report presents a case of a 5-year-old boy with high-risk acute lymphoblastic leukemia (ALL) who received blinatumomab combined with donor lymphocyte infusion (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT). The treatment was well-tolerated, leading to sustained remission.

Background

Acute lymphoblastic leukemia (ALL) is the most prevalent malignant hematological disease in children, with high-risk cases associated with poor prognosis. Allogeneic HSCT is a critical treatment option, yet post-transplant relapse remains a significant challenge.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• A 5-year-old boy with high-risk ALL received blinatumomab and DLI after HSCT.
• Post-treatment minimal residual disease (MRD) assessments showed negative results after blinatumomab.
• The child experienced grade 1 cytokine release syndrome (CRS) during treatment but no severe adverse effects.
• The combined regimen maintained sustained remission.
• Larger prospective trials are needed to confirm the safety and efficacy of this treatment approach.

Clinical Implications

Continuous monitoring of MRD is essential for assessing treatment effectiveness.

Conclusion

This case report presents findings on the combination of blinatumomab with DLI for relapse prevention in pediatric ALL.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. The ASCO Post — Recent Study Findings in Hematologic Malignancies
8. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations | Bone Marrow Transplantation
9. Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia/lymphoma following allogeneic hematopoietic cell transplantation | Blood Cancer Journal
10. Prevention and Treatment of Relapse by Drugs - The EBMT Handbook - NCBI Bookshelf